TCGA-21-5784-01A-01R-1635-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 80
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- COAGULATION+0.450
- PANCREAS_BETA_CELLS+0.450
- TNFA_SIGNALING_VIA_NFKB+0.440
- APICAL_SURFACE+0.420
- OXIDATIVE_PHOSPHORYLATION+0.380
- ESTROGEN_RESPONSE_LATE+0.360
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.350
- XENOBIOTIC_METABOLISM+0.340
- FATTY_ACID_METABOLISM+0.320
- PEROXISOME+0.320
Top 10 suppressed
- MITOTIC_SPINDLE-0.460
- E2F_TARGETS-0.450
- G2M_CHECKPOINT-0.450
- MYC_TARGETS_V2-0.260
- PROTEIN_SECRETION-0.230
- INTERFERON_ALPHA_RESPONSE-0.170
- UV_RESPONSE_DN-0.130
- DNA_REPAIR-0.100
- MYC_TARGETS_V1-0.090
- UNFOLDED_PROTEIN_RESPONSE-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A0HF-01A-11R-A056-07 | — | A | 0.888 |
| 2 | TCGA-BH-A0DS-01A-11R-A056-07 | — | B | 0.871 |
| 3 | SJEPD013_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.870 |
| 4 | MNG350 | — | — | 0.853 |
| 5 | SRR5088845 | — | — | 0.852 |
| 6 | SJEPD021_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.850 |
| 7 | SRR662978 | GTEX | — | 0.848 |
| 8 | sclc2388_S39.txt | — | cohortMD2 | 0.845 |
| 9 | TCGA-56-7731-01A-11R-2125-07 | — | cohortSQ1 | 0.838 |
| 10 | BS_C51RB0YR | low-grade glioma | — | 0.837 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| COAGULATION | 0.450 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.450 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.440 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.420 | Temsirolimus | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.380 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.360 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.350 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.340 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.320 | Inavolisib | — uncovered |
| PEROXISOME | 0.320 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.300 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.290 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.290 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.290 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.280 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.280 | Inavolisib | — uncovered |
| COMPLEMENT | 0.270 | Inavolisib | — uncovered |